Sign In
Buy NVRO
$5.84
+0 (+0%)
At Close: Jul 01, 2025
Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024
04:45pm, Thursday, 10'th Oct 2024
REDWOOD CITY, Calif. , Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, toda
Here's Why you Should Retain Nevro Stock in Your Portfolio Now
01:50pm, Thursday, 26'th Sep 2024
Strength in NVRO's Senza Platform and business diversification plans raises optimism about the stock.
NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI Platform
12:46pm, Wednesday, 25'th Sep 2024
Nevro announces the FDA approval and limited market release of HFX iQ with HFX AdaptivAI.
Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation
08:00am, Tuesday, 24'th Sep 2024
HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in re
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
04:30pm, Thursday, 19'th Sep 2024
REDWOOD CITY, Calif. , Sept. 19, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic p
Nevro to Present at Wells Fargo 2024 Healthcare Conference
04:15pm, Wednesday, 28'th Aug 2024
REDWOOD CITY, Calif. , Aug. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pa
Here's Why You Should Retain Nevro (NVRO) Stock for Now
02:05pm, Tuesday, 20'th Aug 2024
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
04:30pm, Wednesday, 14'th Aug 2024
REDWOOD CITY, Calif. , Aug. 14, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic
Nevro: Not Having My Back
03:47pm, Friday, 09'th Aug 2024
Nevro Corp.'s shares hit fresh lows after revenue guidance reset, reflecting stagnant growth and substantial losses. The company has seen an eventful decade with huge share price fluctuations, but the
Nevro's (NVRO) Q2 Earnings Beat Estimates, Revenues Down Y/Y
02:05pm, Wednesday, 07'th Aug 2024
Nevro's (NVRO) second-quarter earnings beat the Zacks Consensus Estimate while worldwide revenues decline year over over. The company incurs a loss at the operating level.
Nevro Corp. (NVRO) Q2 2024 Earnings Call Transcript
05:54am, Wednesday, 07'th Aug 2024
Nevro Corp. (NYSE:NVRO ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Angie McCabe - VP, IR & Corporate Communications Kevin Thornal - Chief Executive Officer & Pres
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
06:56pm, Tuesday, 06'th Aug 2024
Nevro (NVRO) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.69 per share a year ago.
Nevro Reports Second-Quarter 2024 Financial Results
04:05pm, Tuesday, 06'th Aug 2024
Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and A
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
04:15pm, Thursday, 11'th Jul 2024
REDWOOD CITY, Calif. , July 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pa
Here's Why You Should Retain Nevro (NVRO) Stock for Now
03:01pm, Thursday, 11'th Jul 2024
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
